The company said it was “surprised” by the decision, which followed the ouster of cell and gene therapy officials from the ...

Shares of Capricor Therapeutics CAPR tanked 33% on Friday after it announced that the FDA issued a complete response letter ( ...

Capricor Therapeutics's dip caused by the CRL is a buying opportunity considering the readout of HOPE-3 within 2-3 months.

Capricor Therapeutics (CAPR) announced that the European Medicines Agency, EMA, has granted both Orphan Drug and Advanced Therapy Medicinal Product, ATMP, designations to its lead asset ...

The FDA rejected a Duchenne muscular dystrophy cell therapy from Capricor Therapeutics, as a larger study of the treatment ...

Deramiocel (also known as CAP-1002) is a cell therapy being developed by Capricor Therapeutics for the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy.

In its complete response letter, the FDA cited insufficient evidence establish deramiocel's effectiveness for cardiomyopathy associated with Duchenne muscular dystrophy. The decision comes after CBER ...

Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy. Capricor Therapeutics .

The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10 (b) and 20 (a) of the Securities ...

(RTTNews) - Biotechnology company Capricor Therapeutics (CAPR) Thursday announced the completion of the submission of its Biologics License Applic ...

Deramiocel-treated patients sees a median decline of only 0.5 points after four years. Fourth-year PUL v2.0 decline (0.6 points) is less than one-third of the first year’s drop. A new wave of ...

Capricor Therapeutics (CAPR) announced that the European Medicines Agency, EMA, has granted both Orphan Drug and Advanced Therapy Medicinal Product, ATMP, designations to its lead asset ...